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Barcelona, Vigo, Madrid, Alicante, Palma de Mallorca, and A Coruña, Spain; Ferrara and Bergamo,
Italy; and Breda and Rotterdam, the NetherlandsObjectives This study sought to assess the 2-year outcomes of the population included in the
EXAMINATION (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation
Myocardial Infarction) trial beyond the 1-year prescription period of dual antiplatelet therapy.
Background The EXAMINATION trial compared the performance of everolimus-eluting stents (EES)
versus bare-metal stents (BMS) in an all-comer ST-segment elevation myocardial infarction (STEMI)
population.
Methods This was a multicenter, multinational, prospective, randomized, single-blind, controlled trial
in patients with STEMI. The primary endpoint, which was the combined endpoint of all-cause death,
any recurrent myocardial infarction, and any revascularization, and the endpoints target lesion
revascularization and stent thrombosis were assessed at 2 years.
Results Between December 31, 2008, and May 15, 2010, 1,498 patients were randomized to receive
EES (n ¼ 751) or BMS (n ¼ 747). Compliance with dual antiplatelet regimen was reduced at 2 years to
a similar degree (17.3% vs. 17.2%, p ¼ 0.91). At 2 years, the primary endpoint occurred in 108 (14.4%)
patients of the EES group and in 129 (17.3%) patients of the BMS group (p ¼ 0.11). Rate of target lesion
revascularization was signiﬁcantly lower in the EES group than in the BMS group (2.9% vs. 5.6%;
p ¼ 0.009). Rates of deﬁnite and deﬁnite or probable stent thrombosis were also signiﬁcantly reduced
in the EES group (0.8% vs. 2.1%; p ¼ 0.03, and 1.3% vs. 2.8%; p ¼ 0.04, respectively).
Conclusions The 2-year follow-up of the EXAMINATION trial conﬁrms the safety and efﬁcacy of the
EES compared with BMS in the setting of STEMI. Speciﬁcally, both rates of target lesion
revascularization and stent thrombosis were reduced in recipients of EES without any signs of late
attrition for either of these endpoints. (A Clinical Evaluation of Everolimus Eluting Coronary Stents in
the Treatment of Patients With ST-Segment Elevation Myocardial Infarction: EXAMINATION Study;
NCT00828087) (J Am Coll Cardiol Intv 2014;7:64–71) ª 2014 by the American College of Cardiology
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65First-generation drug-eluting stents (DES) have been heparin, stainless steel, everolimus, or contrast material;Abbreviations
and Acronyms
BMS = bare-metal stent(s)
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
STEMI = ST-segment
elevation myocardial
infarctionshown to be more efﬁcacious as compared with bare-metal
stents (BMS) during the ﬁrst year after the index procedure
(1–3). However, beyond that period, they may suffer from
late hazard, namely stent thrombosis (4,5). The observed
increased rate of stent thrombosis may be related to
a persistent inﬂammatory reaction to the remnant polymeric
coating, delayed endothelialization of the stent or concom-
itant presence of mechanical abnormalities (i.e., stent
malapposition, underexpansion, etc.), and reduced antith-
rombotic protective effect of antiplatelet agents (i.e.,
rebound effect of clopidogrel withdrawal) (6–9). Second-
generation DES have been shown to improve both the
efﬁcacy and safety outcomes compared with ﬁrst-generation
DES and even BMS (10,11). Improvements in hemo-
compatibility and thromboresistance of new coatings may
have played a role in this regard (12).
ST-segment elevation myocardial infarction (STEMI)
represents the paradigm of a thrombotic milieu and a chal-
lenging clinical scenario to test new intracoronary devices
(13,14). The EXAMINATION (Everolimus-Eluting Stents
Versus Bare-Metal Stents in ST-Segment Elevation
Myocardial Infarction) trial (15) was speciﬁcally designed to
evaluate the performance of everolimus-eluting stents (EES)
as compared with BMS in the setting of STEMI. At 1-year
follow-up, rates of both target lesion revascularization and
stent thrombosis were reduced in recipients of EES (16).
Although the results of EES in the EXAMINATION trial
were in accordance with those in more elective contexts (11),
it is unknown whether its safety and efﬁcacy are maintained
beyond 1 year, once dual antiplatelet therapy is usually
withdrawn. Therefore, we sought to evaluate the performance
of EES at 2-year clinical follow-up of patients included in the
EXAMINATION trial.
Methods
Study design and patient population. This was a multicen-
ter multinational, prospective, randomized, single-blind,
controlled trial in patients with STEMI (NCT00828087).
The study design has been previously reported (15). Brieﬂy,
the study had broad inclusion and few exclusion criteria. Any
patient presenting with STEMI within the ﬁrst 48 h after
symptom onset, requiring emergent percutaneous coronary
intervention, with a vessel size ranging between 2.25 mm
and 4.0 mm without other anatomic restrictions could be
included. Exclusion criteria were age younger than 18 years;
pregnancy; known intolerance to aspirin, clopidogrel,Spain; kkErasmus Medical Center, Interventional Cardiology Unit, Rotterdam, the
Netherlands; and {{Cardialysis, Rotterdam, the Netherlands. Dr. Sabaté is a consul-
tant for and has received speaker’s fees from Abbott Vascular, Boston Scientiﬁc, and
Medtronic. Dr. Brugaletta has received speaker’s fees from Abbott Vascular and St.
Jude Medical. Dr. Valgimigli has received honoraria as a public speaker for Terumo,being on chronic treatment with anti-vitamin K agents; and
STEMI secondary to stent thrombosis.
All recruited patients were randomly assigned (ratio 1:1)
to receive 1 of the 2 treatments: EES or cobalt-chromium
BMS. The design of both platforms (EES or BMS) was the
same and corresponded to that of the Multilink Vision stent
(Abbott Vascular, Santa Clara, California). Patients were
blinded to which treatment they received.
Procedures were performed following current practice. At
the index procedure, patients received appropriate anti-
coagulation with either unfractionated heparin or bivalir-
udin. The use of glycoprotein IIb/IIIa inhibitors was left to
the discretion of the investigator. Aspirin (loading dose 250
to 500 mg) and clopidogrel (loading dose of at least 300 mg)
had to be given before percutaneous coronary intervention.
Clopidogrel was prescribed for 1 year (75 mg per day) and
aspirin (100 mg) indeﬁnitely. Manual thrombectomy was
recommended, although other devices could also be used if
considered necessary. Operators were instructed to use only
the assigned stent type at the index procedure. Patients with
multivessel disease needing
staged percutaneous coronary
intervention could also be
included. A recommendation
was made to implant the same
stent type, as per randomization,
in all staged lesions.
The follow-up included clin-
ical visits or telephone contact at
30 days, 6 months, and 1 year,
and were to be continued yearly
up to 5 years. No angiographic follow-up was mandated per
protocol.
Endpoints. The primary endpoint of the study was the
patient-oriented combined endpoint of all-cause death, any
myocardial infarction, or any revascularization at 1 year
(16,17). For the purpose of the current 2-year follow-up, we
have analyzed the patient-oriented endpoint and its indi-
vidual components together with the following stent-derived
endpoints: target vessel myocardial infarction (18); target
vessel and target lesion revascularization; and stent throm-
bosis (17). Detailed deﬁnitions of the endpoints have been
reported elsewhere (15).
Statistical analysis. All analyses were performed by intention
to treat as well as per protocol (if different from allocated by
randomization). Categorical variables were presented as
percentages, and continuous variables as means (mediansThe Medicines Company, Medtronic, Iroko, Merck & Co., Abbott, Eli Lilly and
Company, AstraZeneca, Cordis, CID, and Bayer. Ms. Backx is an employee of
Cardialysis. All other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
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66and interquartile ranges whenever appropriate). The sample
size calculation was based on a 2-sided type I error rate alpha
of 0.05, a randomization ratio of 1:1 (EES group/BMS
group), and a statistical power of at least 86% to detect about
a 30% reduction in the rate of the primary endpoint at 1
year, from 20.5% in the control group to 14.5% in the EES
group. We tested the endpoints statistically with the log-
rank test at a 2-sided 0.05 signiﬁcance level for the
comparison of the EES group with the BMS group. For
time-to-event variables, we constructed survival curves using
Kaplan-Meier estimates. Landmark analyses were per-
formed for primary endpoint, target vessel revascularization,
and deﬁnite/probable stent thrombosis between 1- and
2-year follow-up. Statistical analyses were performed with
SPSS statistical package, version 19.0 (SPSS, Chicago,
Illinois).
Results
Patient demographics and ﬂow chart. Between December
31, 2008 and May 15, 2010, a total of 1,504 patients with
STEMI were recruited, of whom 6 withdrew consent after
randomization. As a result, 1,498 patients were randomly
assigned to receive either an EES (n ¼ 751) or a BMS
(n ¼ 747). Complete 2-year clinical follow-up was ob-
tained in 741 (98.7%) patients of the EES arm and in 733
(98.1%) of the BMS arm. A ﬂowchart of the study is
presented in Figure 1. Baseline clinical and procedural
characteristics were comparable between both arms
(Table 1), and published elsewhere (16). Compliance to
dual antiplatelet regimen (EES vs. BMS) did not differFigure 1. Flowchart of the Study up to 2-Year Follow-Up
A total of 1,504 patients were initially randomized 1:1 to receive either everolimus-el
was obtained in 98.7% of the patients treated with everolimus-eluting stents and 98
infarction; PCI ¼ percutaneous coronary intervention; pts ¼ patients.between groups up to 30 days (99.7% vs. 99.6% at
discharge; p ¼ 0.69; 98.8% vs. 99.4% at 30 days, p ¼
0.26) and became signiﬁcantly different at 6 months
(99.1% vs. 92.8%, p < 0.0001) and at 1 year (97.9% vs.
89.9%, p < 0.0001). Following current guidelines, the
protocol mandated withdrawal of clopidogrel at 12
months unless it was clinically indicated (i.e., patient with
repeat revascularization within the ﬁrst year). As a result,
compliance with dual antiplatelet regimen was reduced at
2-year follow-up to a similar degree (17.3% vs. 17.2%,
p ¼ 0.91) (Fig. 2).
Clinical outcomes at 2 years. Clinical outcomes at 2 years are
presented in Table 2. The patient-oriented endpoint occurred
in 108 (14.4%) patients in the EES group, and 129 (17.3%)
patients in the BMS group (p ¼ 0.11). No signiﬁcant
differences were observed between groups in the rates of
all-cause and cardiac death and any recurrent myocardial
infarction. Rates of target vessel and target lesion revascu-
larization were signiﬁcantly lower in the EES group than in
the BMS group (4.8% vs. 7.9%; p¼ 0.014, and 2.9% vs. 5.6%;
p¼ 0.009, respectively). The rate of deﬁnite stent thrombosis
was signiﬁcantly reduced in the EES group compared with
the BMS group (0.8% vs. 2.1%; p ¼ 0.03). There were 2
episodes of very late deﬁnite stent thrombosis in both groups.
Overall, the rate of deﬁnite or probable stent thrombosis
was also reduced in the EES group at 2 years (1.3% vs. 2.8%;
p ¼ 0.04). There were 3 episodes of very late deﬁnite or
probable stent thrombosis in the EES arm and 2 in the
BMS arm. None of the instances of very late stent thrombosis
were chronologically related to clopidogrel discontinuation.
Kaplan-Meier estimates for the aforementioned outcomesuting stents or cobalt-chromium bare-metal stents. At 2 years, clinical follow-up
.1% of the patients treated with bare-metal stents. AMI ¼ acute myocardial
Table 1. Baseline Clinical and Procedural Characteristics of the Patients
Variable EES Group (n ¼ 751) BMS Group (n ¼ 747)
Age, yrs 60.8  12 61.6  13
Female 117 (16.6) 137 (18.3)
Coronary risk factors
Smoker 544 (62.5) 538 (62.0)
Diabetes mellitus 137 (18.3) 121 (16.2)
Arterial hypertension 347 (46.3) 378 (50.6)
Hyperlipidemia 354 (47.2) 301 (40.3)
Family history of ischemic
heart disease
134 (17.9) 119 (16.0)
Cardiovascular history
Prior MI 33 (4.4) 47 (6.3)
Prior PCI 29 (3.9) 32 (4.3)
Prior CABG 3 (0.4) 7 (0.9)
Prior stroke 12 (1.6) 19 (2.5)
Infarct-related artery
LAD 379 (42.2) 343 (38.9)
LCX 130 (14.5) 132 (15.0)
RCA 380 (42.3) 396 (44.9)
Other 10 (1.1) 10 (1.2)
Total ischemia time, min
Primary PCI, <12 h 215 [150–315] 210 [155–327]
Rescue PCI 449 [330–705] 453 [340–580]
After successful
thrombolysis
828 [284–1,323] 1,105 [750–1,210]
Late-comers, 12 h <48 h 981 [783–1,264] 1,060 [923–1,340]
Anticoagulation regimen
Unfractioned heparin 597 (79.5) 588 (78.7)
Low-molecular-weight
heparin
62 (8.3) 71 (9.5)
Bivalirudin 49 (6.5) 56 (7.5)
Antiplatelet regimen
ASA pre-PCI 692 (92.1) 692 (92.6)
Clopidogrel pre-PCI 710 (94.5) 704 (94.2)
IIb/IIIa inhibitor 400 (53.3) 385 (51.5)
Manual thrombectomy 495 (65.9) 481 (64.4)
Direct stenting 451 (61%) 434 (59.5)
Post-dilation 118 (15.7) 103 (13.7)
Number of stents 1.39  0.7 1.38  0.6
Total stent length 23 [18–35] 23 [18–33]
Biomarkers (peak value)
CK total, IU/l 1,374 [604–3,053] 1,464 [663–2,849]
CK-MB, IU/l 149 [62–321] 142 [60–323]
Troponin, ng/ml 16.4 [4.2–74] 18.2 [4.3–68]
Values are mean  SD, n (%), or median [interquartile range]. p ¼ NS for all variables.
ASA¼ aspirin; BMS¼ bare-metal stent; CABG¼ coronary artery bypass graft; CI¼ conﬁdence
interval; CK ¼ creatine kinase; CK-MB ¼ creatine kinase–myocardial band; EES ¼ everolimus-
eluting stent; LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary
artery; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right
coronary artery.
Figure 2. Dual Antiplatelet Compliance Between Groups for 2 Years
This ﬁgure depicts the percentage of patients receiving dual antiplatelet
treatment at different time points. As per protocol, clopidogrel had to be
withdrawn at 1-year follow-up unless the clinical condition of the patient
dictated the opposite. At 2 years, no difference in the percentage of patients
with aspirin alone was observed between groups. BMS ¼ bare-metal stent(s);
EES ¼ everolimus-eluting stent(s).
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67over 720 days of follow-up are presented in Figures 3A to 3F.
Landmark analyses between 1- and 2-year follow-up did not
demonstrate any signiﬁcant differences regarding the patient-
oriented endpoint (p ¼ 0.461), clinically driven target lesionrevascularization (p ¼ 0.511), or probable/deﬁnite stent
thrombosis (p ¼ 0.672).
Discussion
This report summarizes the long-term outcomes of the ﬁrst
randomized trial speciﬁcally designed in patients with
STEMI who have been treated either with EES, as
a second-generation DES, or with BMS. The main ﬁndings
of the current study are the following. First, the rate of the
patient-oriented composite endpoint did not differ between
groups. Second, the repeat revascularization rate was also
reduced by EES at 2-year follow-up. Third, the rate of
deﬁnite or probable stent thrombosis remained lower with
the use of EES as compared with BMS in the setting of
STEMI. None of these endpoints had very late (>1 year)
attrition following the discontinuation of dual antiplatelet
therapy at 12 months.
Matching the results of the 1-year follow-up (16), this
extended follow-up beyond the prescribed period of dual
antiplatelet therapy did not demonstrate any difference in
favor of the use of EES as assessed by the patient-oriented
composite endpoint. In the same way, the rates of all-cause
death, cardiac death, or recurrent myocardial infarction were
similar between the 2 groups. The use of the patient-related
endpoint has been advocated by the Academic Research
Consortium (17), because this endpoint may more closely
reﬂect the outcomes of patients’ underlying global disease
rather than the speciﬁc effect of the study stent. In this
regard, the patient-oriented endpoint also included any
noncardiac death, any myocardial infarction not related to
the target vessel, and any revascularizations not related to
the target vessel. Similarly, the RESOLUTE AC (RESO-
LUTE All Comers) trial (19) showed a doubled rate of
patient-related outcomes as compared with stent-related
Table 2. Clinical Events at 2 Years
EES Group (n ¼ 751) BMS Group (n ¼ 747) Difference (95% CI) p Value
Primary endpoint, patient-oriented* 108 (14.4) 129 (17.3) 2.9 (6.6 to 0.8) 0.11
Deathy 32 (4.3) 37 (5.0) 0.7 (2.8 to 1.4) 0.52
Cardiac 28 (3.7) 28 (3.7) 0.0 (1.9 to 1.9) 1.0
Vascular 3 (0.4) 3 (0.4) 0.0 (0.6 to 0.6) 0.99
Non-cardiovascular 1 (0.1) 6 (0.8) 0.7 (1.4 to 0.0) 0.57
Myocardial infarctionz 14 (1.9) 18 (2.4) 0.3 (1.5 to 0.9) 0.45
Target vessel related 11 (1.5) 16 (2.1) 0.4 (1.5 to 0.7) 0.46
Non-target vessel related 3 (0.4) 3 (0.4) 0.0 (0.6 to 0.6) 0.99
Revascularization 73 (9.7) 95 (12.7) 3.0 (6.2 to 0.0) 0.05
Target lesion 22 (2.9) 42 (5.6) 2.7 (4.7 to 0.6) 0.01
Target vessel 36 (4.8) 59 (7.9) 3.1 (5.6 to 0.6) 0.009
Non-target vessel 46 (6.1) 52 (7.0) 0.8 (3.3 to 1.7) 0.51
Deﬁnite stent thrombosisx 6 (0.8) 16 (2.1) 1.3 (2.6 to 0.1) 0.03
Deﬁnite/probable stent thrombosisx 10 (1.3) 21 (2.8) 1.5 (2.9 to 0.0) 0.04
Values are n (%), except as noted. *Combined (hierarchical) endpoint of all-cause death, any recurrent myocardial infarction, and any revascu-
larization (16). yDeath was adjudicated according to Academic Research Consortium (ARC) deﬁnitions (17). zMyocardial infarction was adjudicated
according to the World Health Organization extended deﬁnition (18). xStent thrombosis deﬁned according to ARC deﬁnitions (17).
Abbreviations as in Table 1.
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68outcomes at 2-year follow-up, reinforcing the impor-
tance of secondary prevention as adjunctive therapy to
revascularization.
Despite offering no advantages in the primary endpoint as
compared with BMS, EES reduced the need for subsequent
revascularization at 2-year follow-up. For reducing intimal
hyperplasia in stent segments, DES are known to be supe-
rior to BMS (2,20). The time course of restenosis, however,
may differ between types of stents. After BMS implantation,
intimal hyperplasia peaks in the ﬁrst 6 months, and lumen
enlargement may occur from 6 months to 3 years after stent
implantation (21). Conversely, ﬁrst-generation DES exhibit
a potent antiproliferative effect within the ﬁrst months after
implantation, that may vanish over time. In this regard,
Byrne et al. (22) reported the results of angiographic data
during 2-year follow-up in 1,331 patients who were treated
with DES. They found ongoing erosion of the lumen caliber
beyond 6 to 8 months post-index procedure, up to 2-year
follow-up. In a 3-year follow-up study of patients in the
J-Cypher registry, incidences of target lesion revasculariza-
tion in sirolimus-eluting stent–treated lesions were reported
to be 5.5% at 1 year, 8.1% at 2 years, and 10% at 3 years
(23). This phenomenon, called “late catch-up phenom-
enon,” was initially advocated also for EES based on
the 2-year imaging outcome data from the SPIRIT II
(SPIRIT II: A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) trial (24).
Finally, the concerns were proven unfounded when the re-
cently published 5-year data conﬁrmed a reduction in main
cardiac events with the use of EES as compared with ﬁrst-
generation DES (25). In a recent analysis (26), data from
76 randomized trials involving 117,762 patient-years offollow-up demonstrated a continued beneﬁt at long term
(>1 year) by the use of DES. Among the 5 DES analyzed in
that study, EES was the stent with the lowest target vessel
revascularization rate.
In accordance with these previous ﬁndings, our report
extended the beneﬁt of EES over BMS in reducing target
lesion revascularization, to STEMI patients, in whom
restenosis of stented segments supplying infarcted arteries
may be silent or not clinically relevant. To deﬁne the clinical
relevance of the restenosis in STEMI, it is necessary to
design trials that do not include mandatory angiographic
follow-up to avoid the potential oculostenotic reﬂex. In this
regard, all angiographies performed during follow-up in the
EXAMINATION trial were clinically mandated (i.e.,
ischemia-driven) in order to reﬂect real-world clinical
practice.
Stent thrombosis was reduced at 2 years by the use of
EES. Stent thrombosis is an infrequent, but serious,
complication with a high mortality rate. In fact, it can be
manifested by fatal and nonfatal STEMI in >80% of
patients, with a mortality rate up to 25% within 30 days
(6,27). Slow coronary ﬂow, delayed and incomplete healing,
stent malapposition and/or underexpansion, stent length,
lack of stent thrombosis resolution, dissection, exposure of
the blood to prothrombotic subendothelial tissue, failure to
inhibit platelet adhesion and aggregation, and chronic
eosinophilic inﬁltration are some of the mechanisms of stent
thrombosis (8,28–32). Besides these factors, in most clinical
registries, acute coronary syndrome as a clinical condition at
the time of the index procedure repeatedly appears as an
independent predictor of stent thrombosis (13,14). The
timing of stent thrombosis differs between the types of
Figure 3. Kaplan-Meier Estimates for Different Endpoints for 720 Days of Follow-Up
(A) Kaplan-Meier estimates for the primary endpoint. (B) Kaplan-Meier estimates for cardiac death. (C) Kaplan-Meier estimates for recurrent myocardial infarction. (D)
Kaplan-Meier estimates for deﬁnite stent thrombosis. (E) Kaplan-Meier estimates for deﬁnite or probable stent thrombosis. (F) Kaplan-Meier estimates for target lesion
revascularization. At 2-year follow-up, no signiﬁcant differences were observed in the ﬁrst 3 endpoints (A, B, C) between groups. Conversely, signiﬁcant reductions
were observed for the latter 3 endpoints (D, E, F) in favor of the everolimus-eluting stent group. Error bars indicate a point-wise 2-sided 95% conﬁdence interval with
a complementary log-log transformation. Standard error is based on the Greenwood formula.
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70stents. During the ﬁrst months, it may occur after both BMS
and DES implantation; however, beyond 1 year, it is more
frequently observed after ﬁrst-generation DES implantation.
BMS was therefore considered the benchmark for safety
standards for stent evaluation. However, recent studies and
meta-analyses (10,33–35) have demonstrated an excellent
safety proﬁle for second-generation DES. Newer-generation
stents such as the EES have changes in stent design,
including thinner struts, use of cobalt-chromium rather than
stainless steel stents, and thinner and more biocompatible
polymers that may elicit less inﬂammatory response with
a consequent decrease in stent thrombosis. In particular,
EES carries a ﬂuorinated copolymer that may confer
a speciﬁc resistance to thrombosis (12). This may explain the
results of the current study in which 2 stents with an iden-
tical platform (except for the presence of everolimus and
durable polymeric and copolymeric coatings) have been
assessed. In this regard, we could identify the BMS as the
most potent independent predictor of stent thrombosis at
1-year follow-up (30). Of interest, stent thrombosis was
reduced in the early phase, and this beneﬁt persisted up to
2 years without any signs of late erosion of the beneﬁt
beyond 1 year. Certainly, the percentage of patients on dual
antiplatelet regimen at 2 years was comparably reduced
(<20%) in both groups. The present results are consistent
with the similar low rates of stent thrombosis with EES
seen in the Bern-Rotterdam cohort study (versus other
DES) (33) and in an updated analysis from the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR)
(36), in which there was a 67% reduction in the risk of stent
thrombosis compared with BMS. In a recently published
probability analyses, EES had a >80% probability of having
the lowest stent thrombosis rate compared with all other
stent types, including BMS (26).
Study limitations. This study was underpowered to detect
differences in the primary endpoint at any time period.
In fact, the power that the study had to determine a 30%
reduction of the primary endpoint was only 26% at 1
year (16). In the same vein, this trial was also not
powered to detect differences in rare events such as stent
thrombosis. Although data are reassuring and consistent
with other reports on the use of EES, only larger trials
with stent thrombosis as the primary endpoint or
a meta-analysis will provide deﬁnite conclusions in this
regard.
Conclusions
The 2-year follow-up of the EXAMINATION trial
conﬁrms the safety and efﬁcacy of EES compared with
BMS in the setting of STEMI. Speciﬁcally, the rates of both
target lesion revascularization and stent thrombosis were
reduced in recipients of EES, without any signs of late
attrition for both endpoints.Reprint requests and correspondence: Dr. Manel Sabaté,
Cardiology Department, Thorax Institute, IDIBAPS, University of
Barcelona, Hospital Clinic, c/ Villarroel 170, 08036 Barcelona,
Spain. E-mail: masabate@clinic.ub.es.REFERENCES
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